BCBaptiste Le Calvez

Baptiste Le Calvez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Baptiste Le Calvez has a total of 111 co-authors. Here are the top co-authors by number of shared publications:

  • Marion Eveillard

    Hematology Biology Nantes University Hospital Nantes France

    10 shared publications
  • Audrey Grain

    Pediatric Oncology and Hematology, Nantes University Hospital, Nantes, France

    6 shared publications
  • Audrey Grain

    Service d’Hématologie-Oncologie-Immunologie Pédiatrique, CHU Nantes, Nantes, France

    4 shared publications
  • Fanny Rialland

    Nantes Université, CHU Nantes, INSERM, pediatric hematology et oncology department, CIC 1413, F-44000 Nantes, France, University Hospital Centre Nantes, Nantes, France

    3 shared publications
  • Margaux Camuset

    Nantes Université, CHU Nantes, INSERM, pediatric hematology et oncology department, CIC 1413, F-44000 Nantes, France, University Hospital Centre Nantes, Nantes, France

    3 shared publications
  • Marie C. Béné

    CRCI2NA, INSERM U1307, CNRS Université d'Angers/Université de Nantes France

    3 shared publications

Latest Publications

  • Daratumumab in Combination With High‐Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T‐Cell Acute Lymphoblastic Leukemia: A Case Report

    by Perrine Moyer, Baptiste Le Calvez, Caroline Mayeur‐Rousse, Audrey Grain

    Patients with refractory or relapsed T‐cell acute lymphoblastic leukemia (R/R T‐ALL) have dismal outcomes. While immunotherapies are growing opportunities for B‐cell ALL, targeted therapies for T‐ALL remain limited. The CD38 antigen, steadily expressed on T‐ALL blasts, represents a relevant therapeutic target. Daratumumab, an anti‐CD38 monoclonal antibody routinely used in other hematologic malignancies, could be a promising treatment option for T‐ALL. We report here the achievement of a third complete response with the combination of daratumumab, high‐dose cytarabine (18 g/m 2 ), and amsacrine in an 11‐year‐old patient with highly aggressive relapsed T‐ALL, enabling subsequent allogeneic hematopoietic stem cell transplantation.

  • Open Access

    Evaluation of multi-antigen targeting ADCC strategies in pediatric BCP-ALL

    by Audrey Grain, Jocelyn Ollier, Baptiste Le Calvez, Elodie Guiet, Caroline Thomas, Marie-Laure Couec, Margaux Camuset, Fanny Rialland, Marion Eveillard, Emmanuel Scotet, et al.

    Background: Blinatumomab, inotuzumab or autologous anti-CD19 chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, tumor escape through antigenic modulation accounts for almost 40% of subsequent relapses. Multi-antigen targeting strategies should be developed, and it is urgent to identify new targets. Methods: We investigated the extensive immunophenotyping of 13 BCP-ALL from pediatric patients by using the BioLegend Human Cell Surface Marker Screening Kit. Then, to assess whether targeting each antigen with monoclonal antibodies could lead to leukemic cell lysis, long-term antibody-dependent cellular cytotoxicity (ADCC) assays were performed using murine monoclonal antibodies and human T cells armed with murine CD16. Results: 13 highly expressed antigens were selected. With the antibodies tested here, the most significant lysis was observed by targeting CD24 and CD156c. The double targeting of CD24-CD123 appeared to be even more effective. Triple targeting was associated with a reduction in ADCC activity. Conclusion: CD24 therefore emerged as an effective target in BCP-ALL, and the combination of CD24 and CD123 as a potential effective double-targeting strategy. The combination of different recognition modalities (eg, a CAR and CD16) should be tested to determine whether it provides synergistic cytotoxic activity in triple targeting.

  • Uveitis in child treated for acute myeloblastic leukemia: Do not overlook poststreptococcal inflammation

    by Philippe Gardeton, Inés Chabbi, Margaux Camuset, Chloé Couret, Baptiste Le Calvez, Audrey Grain

    Introduction: Poststreptococcal uveitis is among the immune complications following strep infections. Case description: A patient treated for acute myeloblastic leukemia presented with febrile neutropenia 22 days after consolidation chemotherapy including cytarabine. Diagnosed with Streptococcus mitis bacteremia, she subsequently presented with uveitis in her right eye, linked to the previous infection through positive anti-streptolysin O and negative microbiological test results. Topical treatment resulted in complete recovery. Conclusion: This unprecedented presentation of post– S. mitis uveitis reveals the potential for misdiagnosis of ocular manifestations after cytarabine treatment. Furthermore, neutropenia and profound lymphopenia should not prevent both the ophthalmologist and the hematologist from considering poststreptococcal immune complications.


  • Deep Learning‐Based Blood Abnormalities Detection as a Tool for VEXAS Syndrome Screening

    by Cédric De Almeida Braga, Maxence Bauvais, Pierre Sujobert, Maël Heiblig, Maxime Jullien, Baptiste Le Calvez, Camille Richard, Valentin Le Roc'H, Emmanuelle Rault, Olivier Hérault, et al.

    Introduction: VEXAS is a syndrome described in 2020, caused by mutations of the UBA1 gene, and displaying a large pleomorphic array of clinical and hematological features. Nevertheless, these criteria lack significance to discriminate VEXAS from other inflammatory conditions at the screening step. This work hence first focused on singling out dysplastic features indicative of the syndrome among peripheral blood (PB) polymorphonuclears (PMN). A deep learning algorithm is then proposed for automatic detection of these features.Methods: A multicentric dataset, comprising 9514 annotated PMN images was gathered, including UBA1 mutated VEXAS (n = 25), UBA1 wildtype myelodysplastic (n = 14), and UBA1 wildtype cytopenic patients (n = 25). Statistical analysis on a subset of patients was performed to screen for significant abnormalities. Detection of these features on PB was then automated with a convolutional neural network (CNN) for multilabel classification.Results: Significant differences were observed in the proportions of PMNs with pseudo‐Pelger, nuclear spikes, vacuoles, and hypogranularity between patients with VEXAS and both cytopenic and myelodysplastic controls.Automatic detection of these abnormalities yielded AUCs in the range [0.85–0.97] and a F1‐score of 0.70 on the test set. A VEXAS screening score was proposed, leveraging the model outputs and predicting the UBA1 mutational status with 0.82 sensitivity and 0.71 specificity on the test patients.Conclusion: This study suggests that computer‐assisted analysis of PB smears, focusing on suspected VEXAS cases, can provide valuable insights for determining which patients should undergo molecular testing. The presented deep learning approach can help hematologists direct their suspicions before initiating further analyses.


  • Open Access

    Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation?

    by Baptiste Le Calvez, Maxime Jullien, Jean H. Dalle, Cécile Renard, Charlotte Jubert, Arthur Sterin, Catherine Paillard, Anne Huynh, Sarah Guenounou, Bénédicte Bruno, et al.

    For most patients with childhood myelodysplastic syndrome (cMDS), allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remains the only curative option. In the case of increased blasts (cMDS‐IB), the benefit of pretransplant cytoreductive therapy remains controversial. In this multicenter retrospective study, the outcomes of all French children who underwent allo‐HSCT for cMDS reported in the SFGM‐TC registry between 2000 and 2020 were analyzed ( n = 84). The median age at transplantation was 10.2 years. HSCT was performed from matched sibling donors (MSD) in 29% of the cases, matched unrelated donors (MUD) in 44%, haploidentical in 6%, and cord blood in 21%. Myeloablative conditioning was used in 91% of cases. Forty‐eight percent of patients presented with cMDS‐IB at diagnosis (median BM blasts: 8%). Among them, 50% received pretransplant cytoreductive therapy. Five‐year overall survival (OS), cumulative incidence of nonrelapse mortality (NRM), and relapse were 67%, 26%, and 12%, respectively. Six‐month cumulative incidence of grade II–IV acute graft‐versus‐host disease was 46%. Considering the whole cohort, age under 12, busulfan/cyclophosphamide/melphalan conditioning or MUD were associated with poorer 5‐year OS. In the cMDS‐IB subgroup, pretransplant cytoreductive therapy was associated with a better OS in univariate analysis. This seems to be mainly due to a decreased NRM since no impact on the incidence of relapse was observed. Overall, those data may argue in favor of cytoreduction for cMDS‐IB. They need to be confirmed on a larger scale and prospectively.


  • Open Access

    Purplish granules as a cytological signature of cortical developmental disorders caused by pathogenic variants in WDR81

    by Baptiste Le Calvez, Thomas Besnard, Benjamin Cogne, Stéphane Bézieau, Marie C. Béné, Claire Beneteau, Marion Eveillard


  • Neonatal diagnosis of congenital dyserythropoietic anemia type II

    by Apolline Lelard, Baptiste Le Calvez, Simon Bouzy, Marie Laure Couec, Marion Eveillard

  • Open Access

    Bone marrow necrosis in childhood: The hunt for blasts

    by Baptiste Le Calvez, Margaux Camuset, Camille Debord, Audrey Grain, Marion Eveillard

  • Pediatric post‐transplant lymphoproliferative disorder: Do not overlook digestive involvement

    by Baptiste Le Calvez, Batoul Samarji, Gervaise Hubert, Eric Lagrue, Marion Eveillard, Caroline Thomas, Audrey Grain


  • Open Access

    Two Ways of Targeting a CD19 Positive Relapse of Acute Lymphoblastic Leukaemia after Anti-CD19 CAR-T Cells

    by Audrey Grain, Jocelyn Ollier, Thierry Guillaume, Patrice Chevallier, Baptiste Le Calvez, Marion Eveillard, Béatrice Clémenceau

    Background: Therapeutic options for CD19+ relapses after anti-CD19 CAR-T cells are still debated; second infusion of anti-CD19 CAR-T cells, therapeutic antibodies, or targeted therapies can be discussed. Here, we explore the immunophenotyping and lysis sensitivity of CD19+ ALL relapse after anti-CD19 CAR-T cells and propose different therapeutic options for such a high-risk disease. Methods: Cells from successive B-ALL relapses from one patient were collected. A broad immunophenotype analysis was performed. 51Cr cytotoxic assays, and long-term killing assays were conducted using T-cell effectors that are capable of cytotoxicity through three recognition pathways: antibody-dependent cell-mediated cytotoxicity (ADCC), anti-CD19 CAR-T, and TCR. Results: Previously targeted antigen expression, even if maintained, decreased in relapses, and new targetable antigens appeared. Cytotoxic assays showed that ALL relapses remained sensitive to lysis mediated either by ADCC, CAR-T, or TCR, even if the lysis kinetics were different depending on the effector used. We also identified an immunosuppressive monocytic population in the last relapse sample that may have led to low persistence of CAR-T. Conclusion: CD19+ relapses of ALL remain sensitive to cell lysis mediated by T-cell effectors. In case of ALL relapses after immunotherapy, a large immunophenotype will make new therapies possible for controlling such high risk ALL.